Intelligence » Leukemia » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

New Gene Treatment Effective for Some Leukemia Patients

Monday, November 20, 2017 -- A color-enhanced image of a disease-fighting T-cell, reddish, attacking a leukemia cell. A new experimental treatment that genetically engineers a patient’s T-cells to better target and fight cancer cells shows promise.

Breakthrough research brings new procedure closer to helping patients with blood cancer

Friday, November 17, 2017 -- A new procedure that can prevent the potentially lethal side effects of stem cell transplants is a step closer to helping more patients with blood cancers after a breakthrough in understanding of the key mechanism that makes it work.

CAR T-Cell Therapy Approval Starts New Path in Childhood Leukemia

Thursday, November 16, 2017 -- Sarah K. Tasian, MD, discusses the success of CAR T-cell therapy, as well as novel agents and immunotherapies that appear promising in the treatment of children with leukemia.

Vemurafenib Granted FDA Approval for Rare Blood Cancer

Friday, November 17, 2017 -- Vemurafenib (Zelboraf) has been granted approval by the FDA as a treatment for patients with BRAF V600-mutated Erdheim-Chester disease (ECD). This is the first approved therapy for this rare blood disorder.

H3K27M/I mutations promote context-dependent transformation in acute myeloid leukemia with RUNX1 alterations

Thursday, November 16, 2017 -- Neomorphic missense mutations affecting crucial lysine residues in histone H3 genes significantly contribute to a variety of solid cancers. Despite the high prevalence of H3K27M mutations in pediatric glioblastoma and their well-established impact on global histone H3 lysine 27 di- and trimethylation (H3K27me2/3), the relevance of these mutations has not been studied in acute myeloid leukemia (AML). Here, we report the first identification of H3K27M and H3K27I mutations in patients with AML. We find that these lesions are major determinants of reduced H3K27me2/3 in these patients and that they are associated with common aberrations in the RUNX1 gene. We demonstrate that H3K27I/M mutations are strong disease accelerators in a RUNX1-RUNX1T1 AML mouse model, suggesting that H3K27me2/3 has an important

Unrelated HSCT, UCBT May Yield Similar Survival Outcomes in Acute Leukemia

Thursday, November 16, 2017 -- For a meta-analysis, researchers evaluated outcomes data from 9 studies consisting of 6762 patients with an acute leukemia to determine whether HSCT is superior to UCBT.